Home >> Tag Archives: Diagnovus—

Tag Archives: Diagnovus—

Gene-expression assay for DLBCL, 5/13:87

Diagnovus has launched Engauge-cancer-DLBCL, a commercial gene-expression assay for risk stratification and treatment of patients with diffuse large B-cell lymphoma. “Engauge-cancer-DLBCL, which combines a patient’s IPI [International Prognostic Index] score and the results of the gene-expression assay, can more accurately predict outcomes for patients than IPI alone in order to optimize treatment choices for patients,” Ron Levy, MD, leader of the Lymphoma Program at Stanford University School of Medicine, said in a statement.

Read More »